Abstract
Screening small molecule (SM) libraries now replaces traditional methods for vaccine adjuvant discovery. A study by Soni et al. highlights the use of primary human cells in high-throughput screening (HTS), leading to the discovery of a novel SM TLR7/8 agonist, PVP-037. This compound successfully restored vaccine-induced immune responses in aged mice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
